Tumours associated with BAP1 mutations

Summary BAP1 (BRCA1-Associated Protein 1) was initially identified as a protein that binds to BRCA1. BAP1 is a tumour suppressor that is believed to mediate its effects through chromatin modulation, transcriptional regulation, and possibly via the ubiquitin-proteasome system and the DNA damage response pathway. Germline mutations of BAP1 confer increased susceptibility for the development of several tumours, including uveal melanoma, epithelioid atypical Spitz tumours, cutaneous melanoma, and mesothelioma. However, the complete tumour spectrum associated with germline BAP1 mutations is not yet known. Somatic BAP1 mutations are seen in cutaneous melanocytic tumours (epithelioid atypical Spitz tumours and melanoma), uveal melanoma, mesothelioma, clear cell renal cell carcinoma, and other tumours. Here, we review the current state of knowledge about the functional roles of BAP1, and summarise data on tumours associated with BAP1 mutations. Awareness of these tumours will help pathologists and clinicians to identify patients with a high likelihood of harbouring germline or somatic BAP1 mutations. We recommend that pathologists consider testing for BAP1 mutations in epithelioid atypical Spitz tumours and uveal melanomas, or when other BAP1-associated tumours occur in individual patients. Tumour tissues may be screened for BAP1 mutations/loss/inactivation by immunohistochemistry (IHC) (demonstrated by loss of nuclear staining in tumour cells). Confirmatory sequencing may be considered in tumours that exhibit BAP1 loss by IHC and in those with equivocal IHC results. If a BAP1 mutation is confirmed in a tumour, the patient's treating physician should be informed of the possibility of a BAP1 germline mutation, so they can consider whether genetic counselling and further testing of the patient and investigation of their family is appropriate. Recognition and evaluation of larger numbers of BAP1-associated tumours will also be necessary to facilitate identification of additional distinct clinico-pathological characteristics or other genotype-phenotype correlations that may have prognostic and management implications.

[1]  Alexandra Trehin,et al.  BAP1 and Breast Cancer Risk , 2005, Familial Cancer.

[2]  O. Griffith,et al.  COSMIC (Catalogue of Somatic Mutations in Cancer) , 2014 .

[3]  Winship Herr,et al.  E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. , 2007, Molecular cell.

[4]  K. Brown,et al.  A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma , 2012, Pigment cell & melanoma research.

[5]  M. Gill,et al.  Lack of BRAF mutations in Spitz nevi. , 2004, The Journal of investigative dermatology.

[6]  L. Liu,et al.  Loss of the human polycomb group protein BMI1 promotes cancer-specific cell death , 2006, Oncogene.

[7]  E. van den Berg,et al.  Analysis of multiple renal cell adenomas and carcinomas suggests allelic loss at 3p21 to be a prerequisite for malignant development , 1997, Genes, chromosomes & cancer.

[8]  R. Scolyer,et al.  Combined naevus: a benign lesion frequently misdiagnosed both clinically and pathologically as melanoma , 2004, Pathology.

[9]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[10]  P. Komminoth,et al.  Absence of BRAF gene mutations differentiates spitz nevi from malignant melanoma. , 2004, Anticancer research.

[11]  M. Ladanyi,et al.  New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment , 2012, Clinical Cancer Research.

[12]  Jennifer L. Schwartz,et al.  The atypical Spitz tumor of uncertain biologic potential , 2009, Cancer.

[13]  L. Thiberville,et al.  Frequency and prognostic evaluation of 3p21‐22 allelic losses in non‐small‐cell lung cancer , 1995, International journal of cancer.

[14]  S A Forbes,et al.  The Catalogue of Somatic Mutations in Cancer (COSMIC) , 2008, Current protocols in human genetics.

[15]  Gerben Duns,et al.  Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. , 2010, Cancer research.

[16]  C. Cole,et al.  COSMIC (Catalogue of Somatic Mutations in Cancer) , 2014 .

[17]  Erwin G. Van Meir,et al.  BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. , 2008, Cancer research.

[18]  Anindya Dutta,et al.  The Deubiquitinating Enzyme BAP1 Regulates Cell Growth via Interaction with HCF-1* , 2009, The Journal of Biological Chemistry.

[19]  T. Ohta,et al.  The RING Heterodimer BRCA1-BARD1 Is a Ubiquitin Ligase Inactivated by a Breast Cancer-derived Mutation* , 2001, The Journal of Biological Chemistry.

[20]  M. Emi,et al.  Frequent inactivation of the BAP1 gene in epithelioid‐type malignant mesothelioma , 2012, Cancer science.

[21]  A. Goldhirsch,et al.  A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma , 2009, British Journal of Cancer.

[22]  N. Cox,et al.  Germline BAP1 mutations predispose to malignant mesothelioma , 2011, Nature Genetics.

[23]  H. Pass,et al.  BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs , 2012, Journal of Translational Medicine.

[24]  Ashok R Venkitaraman,et al.  Cancer Susceptibility and the Functions of BRCA1 and BRCA2 , 2002, Cell.

[25]  L. Cerroni,et al.  A Distinct Subset of Atypical Spitz Tumors is Characterized by BRAF Mutation and Loss of BAP1 Expression , 2012, The American journal of surgical pathology.

[26]  T. Kristie,et al.  Control of alpha-herpesvirus IE gene expression by HCF-1 coupled chromatin modification activities. , 2010, Biochimica et biophysica acta.

[27]  A. Pichard,et al.  Qualitative comparison of coronary angiograms between 4 french catheters with an Advanced Cardiovascular Injection System and 6 french catheters with manual injection , 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[28]  Huanming Yang,et al.  Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma , 2011, Nature Genetics.

[29]  Aarthi Narayanan,et al.  The coactivator host cell factor-1 mediates Set1 and MLL1 H3K4 trimethylation at herpesvirus immediate early promoters for initiation of infection , 2007, Proceedings of the National Academy of Sciences.

[30]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[31]  D. Buchhagen,et al.  Homozygous deletion, rearrangement and hypermethylation implicate chromosome region 3p14.3‐3p21.3 in sporadic breast‐cancer development , 1994, International journal of cancer.

[32]  A. Sood,et al.  Enhancing Chemotherapy Response with Bmi-1 Silencing in Ovarian Cancer , 2011, PloS one.

[33]  N. Grishin,et al.  BAP1 loss defines a new class of renal cell carcinoma , 2012, Nature Genetics.

[34]  H. Pass,et al.  A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes , 2007, Nature Reviews Cancer.

[35]  T. Nakano,et al.  Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells. , 2011, International journal of oncology.

[36]  Ping Zhu,et al.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells , 2001, The EMBO journal.

[37]  T. Davis,et al.  BMI1 as a novel target for drug discovery in cancer , 2011, Journal of cellular biochemistry.

[38]  K. Rezvani,et al.  Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein , 2010, Leukemia.

[39]  Daniel Birnbaum,et al.  Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia , 2009, British journal of haematology.

[40]  Goberdhan P Dimri,et al.  The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors , 2010, Cell cycle.

[41]  M. Mihm,et al.  Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. , 1999, Human pathology.

[42]  J. Becker,et al.  Germline mutations in BAP1 predispose to melanocytic tumors , 2011, Nature Genetics.

[43]  N. Yoo,et al.  Somatic mutation of a tumor suppressor gene BAP1 is rare in breast, prostate, gastric and colorectal cancers , 2012, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[44]  T. Ohta,et al.  BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. , 2009, Cancer research.

[45]  A. von Deimling,et al.  Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma , 2013, The American journal of surgical pathology.

[46]  S. Gygi,et al.  Defining the Human Deubiquitinating Enzyme Interaction Landscape , 2009, Cell.

[47]  Ivana K. Kim,et al.  Germline BAP1 Inactivation Is Preferentially Associated with Metastatic Ocular Melanoma and Cutaneous-Ocular Melanoma Families , 2012, PloS one.

[48]  S. Jhanwar,et al.  Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. , 1993, Cancer research.

[49]  Matthew B. Wilson,et al.  Tumor Suppressor p16INK4A Regulates Polycomb-mediated DNA Hypermethylation in Human Mammary Epithelial Cells* , 2006, Journal of Biological Chemistry.

[50]  Ziad M. Eletr,et al.  An Emerging Model for BAP1’s Role in Regulating Cell Cycle Progression , 2011, Cell Biochemistry and Biophysics.

[51]  C. Glass,et al.  A histone H2A deubiquitinase complex coordinating histone acetylation and H1 dissociation in transcriptional regulation. , 2007, Molecular cell.

[52]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[53]  Delong Liu,et al.  Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents , 2010, Journal of hematology & oncology.

[54]  G. Hart,et al.  The Ubiquitin Carboxyl Hydrolase BAP1 Forms a Ternary Complex with YY1 and HCF-1 and Is a Critical Regulator of Gene Expression , 2010, Molecular and Cellular Biology.

[55]  M. Cazzola,et al.  Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia , 2010, Leukemia.

[56]  Keith D Wilkinson,et al.  BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression , 1998, Oncogene.

[57]  C. Vandenberg,et al.  Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains , 2002, The EMBO journal.

[58]  Gurpreet W. Tang,et al.  Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.

[59]  M. Vidal,et al.  Role of histone H2A ubiquitination in Polycomb silencing , 2004, Nature.

[60]  M. Speicher,et al.  Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  M. Abdel-Rahman,et al.  Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers , 2011, Journal of Medical Genetics.

[62]  A. Bowcock,et al.  Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma , 2011, Clinical Cancer Research.

[63]  Shirley Wu,et al.  Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16(INK4a). , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[64]  A. Bowcock,et al.  Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas , 2010, Science.

[65]  D. Angeloni.  Molecular analysis of deletions in human chromosome 3p21 and the role of resident cancer genes in disease. , 2007, Briefings in functional genomics & proteomics.

[66]  A. Ashworth,et al.  Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen , 2011, Proceedings of the National Academy of Sciences.

[67]  M. Flaig,et al.  The T1796A mutation of the BRAF gene is absent in Spitz nevi , 2004, Journal of cutaneous pathology.

[68]  D. Pinkel,et al.  Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. , 2000, The American journal of pathology.

[69]  V. Dixit,et al.  Association of C-Terminal Ubiquitin Hydrolase BRCA1-Associated Protein 1 with Cell Cycle Regulator Host Cell Factor 1 , 2009, Molecular and Cellular Biology.

[70]  R. Greenberg,et al.  Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. , 2006, Genes & development.

[71]  S. Baylin,et al.  Double Strand Breaks Can Initiate Gene Silencing and SIRT1-Dependent Onset of DNA Methylation in an Exogenous Promoter CpG Island , 2008, PLoS genetics.

[72]  A. Gazdar,et al.  Malignant mesothelioma: Facts, Myths, and Hypotheses , 2012, Journal of cellular physiology.

[73]  F. Liu,et al.  Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy , 2011, Clinical Cancer Research.

[74]  F. Camacho,et al.  Implication of Polycomb Members Bmi-1, Mel-18, and Hpc-2 in the Regulation of p16INK4a, p14ARF, h-TERT, and c-Myc Expression in Primary Breast Carcinomas , 2006, Clinical Cancer Research.

[75]  Klaas Kok,et al.  Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development , 2012, Human mutation.

[76]  Y. Labrie,et al.  Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian Families with high risk of breast cancer , 2009, Journal of Human Genetics.

[77]  M. Hendzel,et al.  Polycomb group proteins in the DNA damage response: A link between radiation resistance and “stemness” , 2011, Cell cycle.

[78]  D. Jensen,et al.  BAP1, a Candidate Tumor Suppressor Protein That Interacts with BRCA1 , 1999, Annals of the New York Academy of Sciences.

[79]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[80]  M. Wilm,et al.  Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB , 2010, Nature.

[81]  T. Hornyak,et al.  EZH2-Dependent Suppression of a Cellular Senescence Phenotype in Melanoma Cells by Inhibition of p21/CDKN1A Expression , 2011, Molecular Cancer Research.

[82]  Somasekar Seshagiri,et al.  Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation , 2012, Science.

[83]  Haruhiko Koseki,et al.  Polycomb group proteins Ring1A/B link ubiquitylation of histone H2A to heritable gene silencing and X inactivation. , 2004, Developmental cell.

[84]  C. Sander,et al.  The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma , 2011, Nature Genetics.

[85]  D. Elder,et al.  Melanocytic Tumors of Uncertain Malignant Potential: Results of a Tutorial Held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008 , 2010, The American journal of surgical pathology.